We are building a global leading company that creates long-term value for customers, shareholders, and society at scale.
Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety.
With our dedicated team and strong partnerships, we are on a global mission to safeguard every patient's journey, from anesthesia to recovery.
Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF).
Senzime is headquartered in Uppsala, Sweden and has direct sales offices in US and Germany.
In addition, we are present in 30+ additional countries through distributors and partners.

It’s all about patient safety and eliminating preventable complications.
Our solutions are used perioperatively by hundreds of leading hospitals across the globe demanding the most clinically relevant, user friendly and sustainable patient monitors. We’re helping to safeguard every patient during anesthesia and recovery.
Philip Siberg, CEO of Senzime

Join us in celebrating a quarter-century of breakthroughs and advancements in patient monitoring technology!
Throughout the years, we have created new innovations enabling enhanced patient care worldwide.
Our product portfolio includes precision-based patient monitoring solutions, powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function during and after surgery
TetraGraph
TetraGraph is a state-of-the-art neuromuscular monitoring system, powered by the latest electromyography (EMG) technology for accurate and precise monitoring of neuromuscular blockade during surgery. TetraGraph helps clinicians worldwide to optimize the use of neuromuscular blocking agents and reversal drugs, improving patient safety and outcomes.
ExSpiron 2Xi
ExSpiron 2Xi is the market’s only non-invasive monitoring system that measures respiratory volume and minute ventilation for in- and out-patient care. ExSpiron is used for the early detection of changes in the respiratory status of a patient, often after surgery.
Explore TetraGraph, powered by trusted EMG

A world where every clinician is empowered, and every patient assured.
Our mission is to safeguard every patient’s journey, from anesthesia to recovery.
We do this by developing user-friendly precision-based monitoring solutions, based on decades of science, that drive a perioperative digital transformation.
Our commitment propels healthcare providers to reach a new level of patient care, where every clinician is empowered, every patient assured, and the highest standards of care are not just met — they’re invented.
- Expanded US commercial operations
- Received largest US deal ever
- Granted new European TetraGraph system patent
- Secured contract with highest ranked children's hospital in the US
- Secured first Group Purchasing Contract (GPO) in the US
- New studies out confirming TetraGraph's leading accuracy and precision
- Licensee Fukuda Denshi lanched integrated TetraGraph module in Japan
- Commercial breakthrough year with sales growth of 155%
- Growth driven by new clinical guidelines from leading anesthesia societies in US and Europe
- Several large contracts with US hospitals, including largest order ever
- Expanded partnership with Fukuda Denshi
- Outlicenced ExSpiron in Chinese market
- First step launched in partnership with Masimo
- Received ISO 14001 certification
- Launch of TetraSensitive, first EMG sensor for sensitive skin
- Several new studies validating the TetraGraph technology
- Senzime's share cross-traded at US-based OTCQX list
-
FDA 510k-clearance for new disposable sensor intended for monitoring of children
-
Acquisition of Respiratory Motion
-
Strategic license and connectivity agreement with Masimo
-
CE-MDR approval for new disposable sensor intended for small children
-
US and European guidelines for neuromuscular blockade management
-
Inauguration of Senzime’s manufacturing facility in Uppsala, Sweden
-
Senzimes TetraGraph system and new manufacturing facility certified against MDR
-
Listed on Nasdaq Stockholm’s main market
-
Establishing a subsidiary in Germany, receives first breakthrough order from German university hospital
-
Establishing a subsidiary in the US, Senzime Inc
-
Building a sales organisation and receiving breakthrough order from a US university hospital
-
Marketing approval in the US, Japan and South Korea, allowing us to market and sell our products in these markets.
Senzime listed on Nasdaq Stockholm First North Growth Market
-
Licensing agreement with Fukuda Denshi in Japan.
-
Senzime acquires Acacia Designs B.V. thereby obtaining TetraGraph, broadening the product range to include solutions for patients undergoing anesthesia.
-
Senzime acquires MD Biomedical AB, the developer of OnZurf Probe, a new generation of microdialysis catheters.
-
Patent obtained for CliniSenz
-
Senzime is admitted to trading on Aktietorget.
-
The first prototype is completed: CliniSenz – a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.
-
The Crafoord family, represented by Adam Dahlberg, invests in the company.
-
Senzime is founded with the business idea of developing patient-oriented systems for measuring life-critical substances.

Senzime management is a team of people with extensive global experience in the field of medical devices, healthcare and life science.
Senzime Board of Directors is a global team of experts in business development, clinical research and life science development.